Pancreatic Cancer, Research and Clinical Trials

Meet the investigator: Daniel D. Billadeau, Ph.D.

By Nicole Ferrara • December 11, 2019

At the Mayo Clinic Cancer Center, hundreds of researchers dedicate their professional lives to reducing the burden of cancer. Each one has a unique story. In this issue, Daniel D. Billadeau, Ph.D., an oncology researcher at Mayo Clinic in Rochester, Minnesota, talks about his work investigating pancreatic cancer. Dr. Billadeau is also a principal investigator of the Mayo Clinic Pancreatic Cancer SPORE.

Related

This article was originally published in Forefront, Mayo Clinic Cancer Center's online magazine, which ceased publication in December 2020.

cancer pancreatic cancer Pancreatic Cancer research Research and Clinical Trials SPORE
Subscribe to Our Newsletter
Request an Appointment
Find a Clinical Trial

Related Posts

5 cosas que debe saber sobre el cáncer de páncreas

La tasa de supervivencia a cinco años para el cáncer de páncreas es solo del 10,8 %. Aquí hay cinco cosas que todos deberían saber sobre este cáncer mortal.

PET/MRI biomarkers guide personalized treatment for people with pancreatic cancer, study finds

A recent study provides support for Mayo Clinic's use of positron emission tomography (PET) to guide pancreatic cancer treatment decisions.

Mayo Clinic research finds immune system responds to mRNA treatment for cancer

Adding mRNA therapy improves the response to cancer immunotherapy in people who weren't responding to the treatment, Mayo Clinic research shows.